Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis

Current Cancer Drug Targets

Volumn 9, Issue 2, 2009, Pages 189-201

  Cao, Xuefei ^a   Plasencia, Carmen ^a   Kanzaki, Atsuko ^a   Yang, Austin ^b   Burke Jr , Terrence R ^c   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; CASPASE; FAS ANTIGEN; HISTONE H3; JANUS KINASE; PROTEIN BCL 2; PROTEIN P21; SALICYLHYDRAZIDE DERIVATIVE; SC 21; SC 23; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DATABASES, GENETIC; DNA FRAGMENTATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; HYDRAZINES; MICROSCOPY, CONFOCAL; MITOCHONDRIA; PROTEOMICS; REACTIVE OXYGEN SPECIES; RECEPTORS, RETINOIC ACID; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 62549161329     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909787580971     Document Type: Article

References (55)

1. Dy, G. K.; Adjei, A. A. Obstacles and opportunities in the clinical development of targeted therapeutics. Prog. Drug Res. 2005, 63, 19-41.
2. Murdoch, D.; Sager, J. Will targeted therapy hold its promise? An evidence-based review. Curr. Opin. Oncol. 2008, 20, 104-111.
3. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. DrugDiscov. 2004, 3, 711-715.
4. Zheng, C.; Han, L.; Yap, C. W.; Xie, B.; Chen, Y. Progress and problems in the exploration of therapeutic targets. Drug Discov. Today 2006, 11, 412-420.
5. Smith, C. Drug target validation: Hitting the target. Nature 2003, 422, 341, 343, 345. passim.
6. Zhu, F.; Zheng, C. J.; Han, L. Y.; Xie, B.; Jia, J.; Liu, X.; Tammi, M. T.; Yang, S. Y.; Wei, Y. Q.; Chen, Y. Z. Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. Curr. Mol. Pharmacol. 2008, 1, 213-232.
7. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R., Jr.; Pommier, Y.; Milne, G. W. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
8. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W.; Pommier, Y.; Burke, T. R., Jr. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
9. Neamati, N.; Hong, H.; Owen, J. M.; Sunder, S.; Winslow, H. E.; Christensen, J. L.; Zhao, H.; Burke, T. R., Jr.; Milne, G. W.; Pommier, Y. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J. Med. Chem. 1998, 41, 3202-3209.
10. Neamati, N.; Lin, Z.; Karki, R. G.; Orr, A.; Cowansage, K.; Strum- berg, D.; Pais, G. C.; Voigt, J. H.; Nicklaus, M. C.; Winslow, H. E.; Zhao, H.; Turpin, J. A.; Yi, J.; Skalka, A. M.; Burke, T. R., Jr.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45, 5661-5670.
11. Plasencia, C.; Dayam, R.; Wang, Q.; Pinski, J.; Burke, T. R., Jr.; Quinn, D. I.; Neamati, N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol. Cancer Ther. 2005, 4, 1105-1113.
12. Chen, Y. P.; Chen, F. Identifying targets for drug discovery using bioinformatics. Expert. Opin. Ther. Targets 2008, 12, 383-389.
13. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53, 615-627.
14. Brown, J. M.; Attardi, L. D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 2005, 5, 231-237.
15. Abend, M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int. J. Radiat. Biol. 2003, 79, 927-941.
16. Okada, H.; Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4, 592-603.
17. Brown, J. M. Cell status-dead or alive? Nat. Med. 1996, 2, 1055-1056.
18. Ishii, T.; Teramoto, S.; Matsuse, T. GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. Cancer Lett. 2004, 216, 89-102.
19. Pierce, G. B.; Parchment, R. E.; Lewellyn, A. L. Hydrogen peroxide as a mediator of programmed cell death in the blastocyst. Differentiation 1991, 46, 181-186.
20. Lu, H. R.; Zhu, H.; Huang, M.; Chen, Y.; Cai, Y. J.; Miao, Z. H.; Zhang, J. S.; Ding, J. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol. Pharmacol. 2005, 68, 983-994.
21. Mukhopadhyay, P.; Rajesh, M.; Hasko, G.; Hawkins, B. J.; Madesh, M.; Pacher, P. Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytome- try and confocal microscopy. Nat. Protoc. 2007, 2, 2295-2301.
22. Lowe, S. W.; Lin, A. W. Apoptosis in cancer. Carcinogenesis 2000, 27, 485-495.
23. Zhang, J. Y. Apoptosis-based anticancer drugs. Nat. Rev. Drug Discov. 2002, 7, 101-102.
24. Zou, H.; Henzel, W. J.; Liu, X.; Lutschg, A.; Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997, 90, 405-413.
25. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science 1998, 287, 1309-1312.
26. Reed, J. C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3, 17-22.
27. Huang, R. P.; Darland, T.; Okamura, D.; Mercola, D.; Adamson, E. D. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. Oncogene 1994, 9, 1367-1377.
28. Calogero, A.; Cuomo, L.; D'Onofrio, M.; de Grazia, U.; Spinsanti, P.; Mercola, D.; Faggioni, A.; Frati, L.; Adamson, E. D.; Ragona, G. Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines. Oncogene 1996, 73, 2105-2112.
29. Liu, C.; Rangnekar, V. M.; Adamson, E.; Mercola, D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther. 1998, 5, 3-28.
30. Traverse, S.; Gomez, N.; Paterson, H.; Marshall, C.; Cohen, P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 1992, 288(Pt. 2), 351-355.
31. Yaginuma, Y.; Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res, 1992, 52, 4196-4199.
32. Lincet, H.; Poulain, L.; Remy, J. S.; Deslandes, E.; Duigou, F.; Gauduchon, P.; Staedel, C. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma. cells Cancer Lett. 2000, 767, 17-26.
33. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
34. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 2006, 6, 107-121.
35. Nefedova, Y.; Gabrilovich, D. I. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr. Cancer Drug Targets 2007, 7, 71-77.
36. van der Geer, P.; Hunter, T.; Lindberg, R. A. Receptor protein- tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 1994, 70, 251-337.
37. Dijkers, P. F.; van Dijk, T. B.; de Groot, R. P.; Raaijmakers, J. A.; Lammers, J. W.; Koenderman, L.; Coffer, P. J. Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. Oncogene 1999, 78, 3334-3342.
38. Yamauchi, T.; Yamauchi, N.; Ueki, K.; Sugiyama, T.; Waki, H.; Miki, H.; Tobe, K.; Matsuda, S.; Tsushima, T.; Yamamoto, T.; Fu- jita, T.; Taketani, Y.; Fukayama, M.; Kimura, S.; Yazaki, Y.; Na- gai, R.; Kadowaki, T. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J. Biol. Chem. 2000, 275, 33937-33944.
39. Lan, Z.; Wu, H.; Li, W.; Wu, S.; Lu, L.; Xu, M.; Dai, W. Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood 2000, 95, 633-638.
40. Fukuda, R.; Kelly, B.; Semenza, G. L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglan- din E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003, 63, 2330-2334.
41. Gryz, E. A.; Meakin, S. O. Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-dependent, but not nerve growth factor-independent, differentiation and cell cycle arrest in the human neuroblastoma cell line, SY5Y. Oncogene 2003, 22, 8774-8785.
42. Neznanov, N.; Neznanova, L.; Kondratov, R. V.; Burdelya, L.; Kandel, E. S.; O'Rourke, D. M.; Ullrich, A.; Gudkov, A. V. Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. J. Biol. Chem. 2003, 278, 3809-3815.
43. Wang, J.; Chun, H. J.; Wong, W.; Spencer, D. M.; Lenardo, M. J. Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl. Acad. Sci. USA 2001, 98, 13884-13888.
44. Li, H.; Zhu, H.; Xu, C. J.; Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94, 491-501.
45. Yin, X. M. Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-R1 death receptors in hepatocytes. J. Mol. Med. 2000, 78, 203-211.
46. Milhas, D.; Cuvillier, O.; Therville, N.; Clave, P.; Thomsen, M.; Levade, T.; Benoist, H.; Segui, B. Caspase-10 triggers Bid cleavage and caspase cascade activation in FasL-induced apoptosis. J. Biol. Chem. 2005, 280, 19836-19842.
47. Konishi, Y.; Lehtinen, M.; Donovan, N.; Bonni, A. Cdc2 phos- phorylation of BAD links the cell cycle to the cell death machinery. Mol. Cell 2002, 9, 1005-1016.
48. Zhang, J.; Liu, J.; Yu, C.; Lin, A. BAD Ser128 is not phosphory- lated by c-Jun NH2-terminal kinase for promoting apoptosis. Cancer Res. 2005, 65, 8372-8378.
49. Huggenvik, J. I.; Collard, M. W.; Kim, Y. W.; Sharma, R. P. Modification of the retinoic acid signaling pathway by the catalytic subunit of protein kinase-A. Mol. Endocrinol. 1993, 7, 543-550.
50. Rochette-Egly, C.; Oulad-Abdelghani, M.; Staub, A.; Pfister, V.; Scheuer, I.; Chambon, P.; Gaub, M. P. Phosphorylation of the reti- noic acid receptor-alpha by protein kinase A. Mol. Endocrinol. 1995, 9, 860-871.
51. Zhao, Q.; Tao, J.; Zhu, Q.; Jia, P. M.; Dou, A. X.; Li, X.; Cheng, F.; Waxman, S.; Chen, G. Q.; Chen, S. J.; Lanotte, M.; Chen, Z.; Tong, J. H. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 2004, 78, 285-292.
52. Aleem, E.; Kiyokawa, H.; Kaldis, P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat. Cell Biol. 2005, 7, 831-836.
53. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 73, 261-291.
54. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47, 936-942.
55. Munshi, A.; Hobbs, M.; Meyn, R. E. Clonogenic cell survival assay Methods Mol. Med. 2005, 770, 21-28.